Nabriva Therapeutics, an Austrian clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, has hired Elyse Seltzer as Chief Medical Officer. She replaces Dr William Prince, who will move to Senior Vice President, Clinical Science.
Based in Philadelphia, US, Dr Seltzer will supervise medical and regulatory aspects of clinical development and medical affairs for Nabriva and contribute to the company’s clinical development strategy. She will work with Dr Steven Gelone, the recently appointed Chief Development Officer, as well as the clinical operations team, to execute Nabriva’s clinical development programme, including the planned Phase III clinical trials of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP).
Dr Prince will be responsible for the Phase I and scientific programmes required to support the lefamulin development programme for CABP and additional indications.
Dr Seltzer joins Nabriva from GlaxoSmithKline (GSK), where she was Vice President of Global Clinical Sciences and Operations.
